Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1977 1
1978 1
1979 1
1982 2
1986 2
1988 1
1990 2
1991 3
1992 2
1995 5
1996 1
1997 4
1998 4
1999 4
2000 3
2001 7
2002 12
2003 10
2004 5
2005 4
2006 2
2007 1
2009 6
2010 9
2011 9
2012 7
2013 7
2014 11
2015 12
2016 20
2017 10
2018 19
2019 10
2020 6
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27294163

192 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T. Lotem M, et al. J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18. J Immunol Res. 2016. PMID: 27294163 Free PMC article. Clinical Trial.
Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.
Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS. Sarnaik AA, et al. Clin Cancer Res. 2011 Feb 15;17(4):896-906. doi: 10.1158/1078-0432.CCR-10-2463. Epub 2010 Nov 24. Clin Cancer Res. 2011. PMID: 21106722 Free PMC article. Clinical Trial.
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J. Nicholaou T, et al. Cancer Immunol Immunother. 2011 Nov;60(11):1625-37. doi: 10.1007/s00262-011-1041-3. Epub 2011 Jun 23. Cancer Immunol Immunother. 2011. PMID: 21698545 Clinical Trial.
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS, Gore M, Thompson JF, Davis ID, McArthur GA, Walpole E, Smithers M, Cerundolo V, Dunbar PR, MacGregor D, Fisher C, Millward M, Nathan P, Findlay MPN, Hersey P, Evans TRJ, Ottensmeier CH, Marsden J, Dalgleish AG, Corrie PG, Maria M, Brimble M, Williams G, Winkler S, Jackson HM, Endo-Munoz L, Tutuka CSA, Venhaus R, Old LJ, Haack D, Maraskovsky E, Behren A, Chen W. Cebon JS, et al. J Immunother Cancer. 2020 Apr;8(1):e000410. doi: 10.1136/jitc-2019-000410. J Immunother Cancer. 2020. PMID: 32317292 Free PMC article. Clinical Trial.
192 results